BIOLINERX     Print Page  Close Window

SEC filings
F-1
BIOLINERX LTD. filed this Form F-1 on 10/02/2012
Entire Document
 
F - 14

 
 
BioLineRx Ltd.
 
CONSOLIDATED CASH FLOW STATEMENTS
 
   
Year ended December 31,
   
Convenience translation into USD (Note 1b)
 
   
2009
   
2010
   
2011
   
2011
 
   
NIS in thousands
   
In thousands
 
APPENDIX
                       
                         
Adjustments required to reflect net cash used in operating activities:
                       
Income and expenses not involving cash flows:
                       
Depreciation and amortization
    1,754       1,814       1,563       398  
Impairment of intangible assets
    584       1,846       88       22  
Retirement benefit obligations
    (63 )     79       53       14  
Long-term prepaid expenses
    (880 )     954       (8 )     (2 )
Loss on sale of property and equipment
    1       -       -       -  
Exchange differences on cash and cash equivalents
    (1,489 )     6,049       (1,920 )     (489 )
Gain on fair value adjustments to financial assets at fair value through profit or loss
    (98 )     -       -       -  
Share-based compensation
    3,399       6,557       3,983       1,015  
Interest and exchange differences on short-term deposits
    -       296       (1,597 )     (407 )
Interest and linkage on bank loan
    -       -       (14 )     (4 )
Interest and exchange differences on restricted deposits
    (204 )     143       (7 )     (2 )
      3,004       17,738       2,141       545  
                                 
Changes in operating asset and liability items:
                               
Decrease (increase) in trade accounts receivable and other receivables
    (29,877 )     34,798       1,847       471  
Increase (decrease) in accounts payable and accruals
    3,895       (19,305 )     3,457       881  
      (25,982 )     15,493       5,304       1,352  
                                 
      (22,978 )     33,231       7,445       1,897  
                                 
Supplementary information on investing and financing activities not involving cashflows:
                               
Credit received in connection with purchase of property and equipment
    -       104       265       68  
Credit received in connection with purchase of intangible assets
    245       100       -       -  
                                 
Supplementary information on interest received in cash
    443       1,013       1,825       465  
 
The accompanying notes are an integral part of the financial statements.